Iron, Cobalt, Nickel, Vanadium, Molybdenum, Or Palladium Patents (Class 424/646)
-
Publication number: 20130344113Abstract: The present invention relates to a food product which has been fortified in iron content, comprising a Fe3O4 sphere. The present invention also relates to an iron-containing additive for use in the above food product, in the form of a Fe3O4 sphere. The present invention further relates to a method for preparing the above food product, comprising the steps of adding or mixing the iron-containing additive in solid or dispersed form with the food product, wherein the iron-containing additive is in the form of a Fe3O4 sphere.Type: ApplicationFiled: June 22, 2012Publication date: December 26, 2013Applicant: MAGQU CO. LTD.Inventors: Shieh-Yueh Yang, Che-Chuan Yang
-
Publication number: 20130344166Abstract: A topical mixture intended to reduce undesirable Iron levels in the cells to optimize Mitochondrial functioning. A method of reducing undesirable levels of Iron in the cells to optimize Mitochondrial functioning.Type: ApplicationFiled: June 25, 2012Publication date: December 26, 2013Inventor: PIERRE ERNEST LOUBET
-
Publication number: 20130344167Abstract: The present invention relates to a galenic composition suitable for administration to a non-human animal, including at least the following three components: one or more active principles; an agent for accelerating delitescence; an agent for delaying delitescence, wherein the agent for accelerating delitescence an the agent for delaying delitescence are integrated in the composition so as to form a matrix with the controlled release of the active principle(s). The invention also relates to the uses of said compositions, as well as to a method for measuring the in vitro delitescence thereof.Type: ApplicationFiled: November 27, 2011Publication date: December 26, 2013Applicant: VETALIS SARLInventors: Laurent Chery, Jean-Pierre Wajda-Dubos
-
Publication number: 20130336902Abstract: A personal care composition is disclosed comprising a di-amido gellant, wherein the di-amido gellant has a formula: wherein R1 and R2 are aminofunctional end-groups which may be the same or different, and L is a linking moiety of molecular weight from 14 to 500 g/mol. The personal care composition may take a variety of forms such as a leave-on composition or an emulsion and/or may comprise one or more actives or agents.Type: ApplicationFiled: June 13, 2012Publication date: December 19, 2013Inventors: SUSANA FERNANDEZ PRIETO, JOHAN SMETS, BEATRIU ESCUDER GIL, JUAN FELIPE MIRAVET CELADES, VICENT JOSEP NEBOT CARDA, PAUL ROBERT TANNER
-
Publication number: 20130336918Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventor: Ardelyx, Inc.
-
Publication number: 20130336921Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y and A are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventors: Jason G. Lewis, Jeffrey W. Jacobs, Nicholas Reich, Michael R. Leadbetter, Noah Bell, Han-Ting Chang, Tao Chen, Marc Navre, Dominique Charmot, Christopher Carreras, Eric Labonte
-
Publication number: 20130336919Abstract: Compounds having activity as phosphate transport inhibitors, more specifically, inhibitors of intestinal apical membrane Na/phosphate co-transport, are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein X, Y, R1 and R2 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: January 4, 2013Publication date: December 19, 2013Applicant: ARDELYX, INC.Inventor: Ardelyx, Inc.
-
Publication number: 20130330417Abstract: Nanocellulose foams containing at least one active ingredient and methods of preparing such nanocellulose foams containing one or more active ingredients are provided herein. In some embodiments, a method for preparing nanocellulose foam containing active ingredients may include forming a liquid mixture of nanocellulose, wherein the nanocellulose is at least one of dispersed, suspended or gelled in the liquid mixture; drying the liquid mixture of nanocellulose to form a nanocellulose foam; and mixing at least one active ingredient into at least one of the liquid mixture of nanocellulose or the nanocellulose foam. In some embodiments, a nanocellulose structure may include a nanocellulose foam comprising at least one of a carboxylate group, a hydroxyl group, or a sulfate group bonded to an active ingredient. In some embodiments, the nanocellulose structures are enhanced or crosslinked with metal cations.Type: ApplicationFiled: June 7, 2013Publication date: December 12, 2013Inventors: Hong Dong, James F. Snyder
-
Publication number: 20130323324Abstract: Compositions that include vanadium or vanadyl chelated to an amino acid are disclosed, particularly vanadium or vanadyl chelated to creatine, arginine, citrulline, taurine, phenylalanine, glutamine, glutathione, leucine, or combinations thereof. In addition, compositions that included blended forms of such chelates and/or vanadyl sulfate and one or more unbound amino acids. Still further, the compositions disclosed may further include one or more additional proteins, amino acids, vitamins, minerals, or combinations thereof, which impart an additional nutritional and/or therapeutic benefit to the composition.Type: ApplicationFiled: June 1, 2013Publication date: December 5, 2013Inventor: Franco Cavaleri
-
Publication number: 20130309280Abstract: The present invention provides a cell eradication method and a cell eradication principle for necrotizing a cell by agitating a cell using a physical turning force from the impression of an AC magnetic field, after preparing a magnetic nanowire having a dipole and introducing the magnetic nanowire into a cell. Therefore, the composition for inducing cell eradication of the present invention, when applied to a cell that is requested to be removed such as a cancer cell, can eradicate the cell by applying a physical impact through the rotation of the nanowire introduced inside the cell. Additionally, the heat generated from induced current from the magnetic field impression can add an effect of thermotherapy, and also, attaching a drug to the surface of the nanowire enhances the treatment effects.Type: ApplicationFiled: January 31, 2012Publication date: November 21, 2013Applicant: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATIONInventors: Sung Hoi Choi, Jung Rae Park, Young Keun Kim
-
Publication number: 20130309322Abstract: The present invention provides formulas for producing compositions for the structural/functional nutritional support for those who struggle with poor focus, concentration and/or memory. In addition, the present invention provides compositions comprising nutritional/botanical factors helpful to those who subjectively experience transient mental fatigue or poor cognitive function. The compositions of this invention consist primarily of the following ingredients B-complex vitamins, antioxidants, minerals, phosphatidyl serine (PS), choline, dimenthyl-aminoethanol (DMAE), docosahexaenoic acid (DHA), L-pyroglutamic acid, as well as herbal extracts from Bacopa monniera, Vinca minor, and Huperzia serrata. The present invention also relates to the administration of these compounds to alleviate mental fatigue or poor cognitive function.Type: ApplicationFiled: November 20, 2012Publication date: November 21, 2013Applicant: FACTOR NUTRITION LABS, LLCInventor: Kyl L. SMITH
-
Publication number: 20130295022Abstract: The present invention provides a highly tolerable, hydrating lanolin containing foamable composition for administration to the skin, body surface, body cavity or mucosal surface, e.g., the mucosa of the nose, mouth, eye, ear, respiratory system, vagina or rectum. The foamable composition includes lanolin, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.Type: ApplicationFiled: June 6, 2013Publication date: November 7, 2013Inventors: Doron Friedman, Alex Besonov, Dov Tamarkin, Meir Eini
-
Publication number: 20130295196Abstract: The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.Type: ApplicationFiled: January 20, 2012Publication date: November 7, 2013Applicant: ASSISTANCE PUBLIQUE-HOPITAUX DE PARISInventor: Eric Konofal
-
Publication number: 20130295179Abstract: The present application relates to compositions for use in a method of treating and/or preventing mental and behavioral disorders and/or improving mental health and cognitive functions in a subject, comprising: a) Docosahexaenoic acid (DHA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; b) Eicosapentaenoic acid (EPA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; c) ?-linolenic acid (GLA) and/or the pharmaceutically acceptable derivatives and/or precursors thereof; and at least a psychostimulant compound selected among methylphenidate HCl, atomoxetine, amphetamine, gamma-hydroxybutyrate, dextroamphetamine, sibutramine, methylenedioxymethamphetamine, and/or an anxiolytic compound selected among fluoxatine, sertraline, paroxetine, fluoroxamine, citralopram, venlafaxine, bupropion, nefazodone, and mirtazapine.Type: ApplicationFiled: April 12, 2013Publication date: November 7, 2013Inventors: Christian TERREAUX, Eleonora HOMBERGER, Burkhard KRIWET, Eduardo BARRAGAN PEREZ
-
Publication number: 20130295146Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises: a) a lipid fraction comprising at least one of docosahexaneoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdene, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.Type: ApplicationFiled: July 2, 2013Publication date: November 7, 2013Applicant: N.V. NUTRICIAInventors: Robert Johan Joseph HAGEMAN, Mattheus Cornelis DE WILDE, Patrick Joseph Gerardus Hendrikus KAMPHUIS
-
Patent number: 8575212Abstract: Embodiments of the invention relate to a method of making a mineral product. The method includes contacting a carboxylic acid and an inorganic mineral compound sufficient to form a solution, reacting the solution over a period of time sufficient to provide a mineral chelated compound, transferring the mineral chelated compound to one or more molds prior to the compound substantially solidifying and reducing the size of the mineral chelated compound sufficient to provide a rapidly soluble mineral chelated product.Type: GrantFiled: July 13, 2010Date of Patent: November 5, 2013Assignee: Ralco Nutrition, Inc.Inventors: Brian Jon Knochenmus, Jon Kent Knochenmus, Richard Dale Lamb, Myrra Arlene Lamb
-
Publication number: 20130287864Abstract: The object of the invention is to provide a bioactive agent in which the bioactive effectiveness of ferric iron salt and/or ferric ferrous iron salt contained therein is stabilized, making long term preservation possible, so that the bioactive agent can be useful as an original solution for medical use, as a soil conditioner, or the like. An iron-magnesium mixture solution is provided in the invention, wherein the iron-magnesium mixture solution is produced by mixing an aqueous solution containing a ferric iron salt and/or a ferric ferrous iron salt in a concentration of not less than 0.5 mol/L as iron in the ferric iron salt and/or the ferric ferrous iron salt, and an aqueous solution containing a magnesium salt in a concentration of not less than 0.2 mol/L as magnesium in the magnesium salt.Type: ApplicationFiled: November 12, 2010Publication date: October 31, 2013Applicant: I.B.E. CO., LTDInventor: Mie Makino
-
Patent number: 8568759Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.Type: GrantFiled: December 14, 2010Date of Patent: October 29, 2013Assignee: W. Neudorff GmbH KGInventor: Diana L. Parker
-
Patent number: 8568792Abstract: A mixed metal compound for pharmaceutical use is free from aluminium and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.Type: GrantFiled: July 1, 2010Date of Patent: October 29, 2013Assignee: Cytochroma Development Inc.Inventors: Norman B Roberts, Maurice Webb, Benjamin J Rankin
-
Patent number: 8562860Abstract: A method for activating hydrogen molecules dissolved in water and stabilizing the concentration of the hydrogen molecules is provided. The method for activating and stabilizing hydrogen molecules dissolved in water is characterized by allowing hydrogen ions to coexist with the hydrogen molecules.Type: GrantFiled: July 5, 2007Date of Patent: October 22, 2013Assignee: Spring Co., Ltd.Inventor: Osao Sumita
-
Patent number: 8557290Abstract: The present invention relates to nanoconjugates. In particular, the present invention provides nanoconjugates for diagnostic (e.g., imaging), research, and clinical (e.g., targeted treatment) applications.Type: GrantFiled: March 13, 2009Date of Patent: October 15, 2013Assignee: Northwestern UniversityInventors: Ai-Guo Wu, Tatjana Paunesku, Gayle E. Woloschak
-
Patent number: 8551513Abstract: A scaffold for implantation into a mammal to facilitate vessel growth in repair, regeneration, and/or proliferation of bodily tissue, where the scaffold is based on a borate, silicate, or phosphate, glass-former and is biodegradable upon implantation in mammals. The scaffold includes one or more trace elements from the group consisting of Cu, F, Fe, Mn, Mo, Ni, Si, Sr, and Zn which are released into the host to support vessel growth. A method involves implantation of such scaffolds.Type: GrantFiled: October 1, 2012Date of Patent: October 8, 2013Assignee: The Curators of the University of MissouriInventors: Steven B. Jung, Delbert E. Day
-
Patent number: 8546423Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: GrantFiled: October 22, 2009Date of Patent: October 1, 2013Assignee: MPEX Pharmaceuticals, Inc.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
-
Patent number: 8545820Abstract: Compositions containing metal ions bound into a titanate are described which have demonstrated an ability to suppress bacterial growth of a number of organisms associated with periodontal disease and caries.Type: GrantFiled: July 14, 2011Date of Patent: October 1, 2013Assignees: Savannah River Nuclear Solutions, LLC, University of Washington Center for CommercializationInventors: David T. Hobbs, Mark C. Elvington, John Wataha, Whasun O. Chung, R. Bruce Rutherford, Daniel C. Chan
-
Publication number: 20130243720Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutica composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.Type: ApplicationFiled: June 27, 2012Publication date: September 19, 2013Inventors: Chad Huval, Pradeep Dhal, Stephen Randall Holmes-Farley
-
Patent number: 8535660Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.Type: GrantFiled: November 7, 2011Date of Patent: September 17, 2013Assignee: Argent Development Group, LLCInventors: John C. Morrison, Kenneth R. Greathouse
-
Patent number: 8535710Abstract: A method for treating a wound, and a dressing for wound care management comprising a three-dimensional body of glass-based fibers comprising one or more glass-formers selected from the group consisting of P2O5, SiO2, and B2O3; at least about 25 wt % of the fibers have a diameter between about 200 nm and about 4000 nm, and a length:width aspect ratio of at least about 10. In another form, the glasses are in the form of particles in an ointment or cream applied to a wound. In yet other forms the glasses are employed as fibers formed into sutures for closing a wound, or as particles in a surgical glue for closing a wound.Type: GrantFiled: April 9, 2012Date of Patent: September 17, 2013Assignee: The Curators of the University of MissouriInventors: Steven B. Jung, Delbert E. Day
-
Patent number: 8535659Abstract: The present invention relates to different nutritional supplements to be administered to, or taken by, pregnant women during the first, second and third trimesters of pregnancy.Type: GrantFiled: May 21, 2009Date of Patent: September 17, 2013Assignee: Argent Development Group, LLCInventors: John C. Morrison, Kenneth R. Greathouse
-
Publication number: 20130236548Abstract: A method for treating a cancer is disclosed, which comprises: administering an effective amount of Fe-based particles to a subject in need, wherein the Fe-based particles have core-shell structures. Herein, each Fe-based particle of the present invention comprises: an Fe elemental core with zero valent irons; and a covering layer formed on partial or whole surface of the Fe elemental core, wherein a material of the covering layer is a metal, a metal doped with dopants, a metal alloy, a polymer, carbon, a metal oxide or a nonmetal oxide, and the shape of the Fe-based particles is a rod, a sphere, a cubic or a dumbbell, with the proviso that the metal is not Au.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Applicant: NATIONAL CHENG KUNG UNIVERSITYInventors: Dar-Bin SHIEH, Li-Xing YANG, Ya-Na WU
-
Publication number: 20130236566Abstract: Methods for identifying patients with anemia, distinguishing thalassemia-trait anemia from iron-deficiency anemia, and identifying pre-anemic patients several weeks before anemia becomes clinically detectable. Also, methods for detecting blood doping in athletes and for optimizing therapy with erythropoiesis stimulating agents or iron supplementation. Computer-readable storage devices and systems, e.g., for use in the described methods.Type: ApplicationFiled: September 16, 2011Publication date: September 12, 2013Applicant: THE GENERAL HOSPITAL CORPORATIONInventor: John M. Higgins
-
Publication number: 20130236507Abstract: A method for treating a cancer is disclosed, which comprises: administering an effective amount of Fe-containing alloy particles to a subject in need, wherein a material of each Fe-containing alloy particle is an alloy comprising a first metal of Fe and a second metal.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Applicant: NATIONAL CHENG KUNG UNIVERSITYInventors: Dar-Bin SHIEH, Li-Xing YANG, Ya-Na WU
-
Patent number: 8529963Abstract: The present invention is directed to a method for preparing colloidal dispersions of precious metal nanoparticles selected from the group consisting of Pt, Au, Pd, Ag, Rh, Ru and mixtures or alloys thereof, and to a method for isolating such precious metal nanoparticles from these colloidal dispersions. The colloidal dispersions are prepared by reducing suitable precious metal precursor compounds in aqueous alkaline solutions at reaction temperatures between 40 and 70° C. and a pH?12.0 in the presence of polysaccharides with average molecular weights (Mw) in the range of 300,000 to 1,000,000. The precious metal nanoparticles are isolated after decomposing the polysaccharide by heating the colloidal dispersions to temperatures >80° C. The nanoparticles can be used for the manufacture of core/shell-type catalyst materials and for electronic, decorative and medical applications.Type: GrantFiled: January 9, 2009Date of Patent: September 10, 2013Assignee: Umicore AG & Co. KGInventors: Dan V. Goia, Benjamin Morrow, Egon Matijevic, Krishna Balantrapu, Brendan P. Farrell
-
Patent number: 8529935Abstract: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.Type: GrantFiled: January 29, 2010Date of Patent: September 10, 2013Assignees: Mero S.R.L., Novagenit S.R.L.Inventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano, Enzo Meani, Edgardo Cremascoli
-
Patent number: 8524735Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: GrantFiled: October 22, 2009Date of Patent: September 3, 2013Assignee: MPEX Pharmaceuticals, Inc.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
-
Patent number: 8524734Abstract: Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.Type: GrantFiled: October 22, 2009Date of Patent: September 3, 2013Assignee: MPEX Pharmaceuticals, Inc.Inventors: Mark W. Surber, Keith A. Bostian, Michael N. Dudley, Olga Lomovskaya, David C. Griffith
-
Publication number: 20130225906Abstract: This invention relates to a material for medical use that comprises biocompatible nanoparticles having superparamagnetic properties, where the superparamagnetic properties of said nanoparticles are used to localize their action on a determined space or tissue. In particular, said nanoparticles having superparamagnetic properties are composed of magnetite. The material according to the invention has various applications, both in surgical and in therapeutic treatments.Type: ApplicationFiled: September 9, 2011Publication date: August 29, 2013Applicant: NANOPHTHALMICS, LLCInventors: Roberto Zysler, Alejandro Berra, Pablo Gurman, Orlando Auciello, Mario Joaquin Saravia
-
Patent number: 8512688Abstract: A process for preparing a formulation comprising a complex comprising an effective amount of ferrous iron bound to a pharmaceutically acceptable cationic resin and at least one pharmaceutically acceptable carrier is described. Such a formulation may optionally include other desirable dietary supplements including, e.g., vitamins, omega fatty acids, and/or fluoride. The formulation is particularly well adapted for pediatric use, but is also useful for use in adult populations.Type: GrantFiled: September 12, 2012Date of Patent: August 20, 2013Assignee: Tris Pharma Inc.Inventors: Ketan Mehta, Yu-Hsing Tu, Mahendra Shah
-
Patent number: 8512760Abstract: A process for the production of an aqueous dispersion of metal nano particles comprising palladium is provided. The process comprises the admixture of a water soluble organic polymer, a palladium salt and a first reducing agent to an aqueous liquid. The first reducing agent is a metal-containing polymer which has reducing properties or a saccharide which has reducing properties. The nano particles can include a second metal. The dispersions can be used as catalysts for electroless plating, to produce heterogeneous catalysts and in the production of anti-microbial devices and compositions.Type: GrantFiled: November 21, 2008Date of Patent: August 20, 2013Assignee: The University Court of the University of DundeeInventors: James Anthony Cairns, Roderick Allan George Gibson, Graham James Berry
-
Publication number: 20130202694Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Inventors: Daniel Henry WYROBNIK, Isaac Harry Wyrobnik
-
Publication number: 20130202696Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Inventors: Daniel Henry WYROBNIK, Isaac Harry Wyrobnik
-
Publication number: 20130189374Abstract: The present invention generally relates to methods and compositions useful in enhancing iron absorption in a patient. The methods and compositions of the present invention may be used independently to promote and/or maintain iron absorption in a patient or may be used in combination with one or more other compositions used in the treatment of one or more diseases having iron deficiency associated therewith.Type: ApplicationFiled: July 20, 2012Publication date: July 25, 2013Applicant: DRUGTECH CORPORATIONInventors: Jonathan David Bortz, Mitchell Kirschner
-
Publication number: 20130189345Abstract: A variety of article and systems including wound care systems, methods for making the wound care systems, bactericidal, and methods for treating wounds using these systems are disclosed. The wound care systems may include a first material comprising one or more fibers or porous media. The one or more fibers or porous media may be coated with a second material that is capable of inhibiting the growth of bacteria and killing the bacteria to render the wound care system sterile, increasing the absorbency of the first material, or both upon exposure to light. The first material may be cotton, or any suitable fibrous material, the second material may be TiO2, and the light may be UV or visible light. A variety of methods including ALD may be used to coat the first material.Type: ApplicationFiled: January 9, 2013Publication date: July 25, 2013Applicant: OLD DOMINION UNIVERSITY RESEARCH FOUNDATIONInventor: Old Dominion University Research Foundation
-
Publication number: 20130183277Abstract: Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine.Type: ApplicationFiled: December 19, 2012Publication date: July 18, 2013Inventor: Jon D. Kaiser
-
Publication number: 20130177659Abstract: Tetrathiomolybdate is for use in therapy of a condition requiring reduced metabolism of an organ or whole body, e.g. myocardial infection, stroke or ischaemia-reperfusion injury.Type: ApplicationFiled: September 28, 2012Publication date: July 11, 2013Applicant: Magnus TTM ICInventor: Magnus TTM IC
-
Publication number: 20130171258Abstract: The present invention relates to a pharmaceutical composition for elevating radiation-sensitivity of cancer cells, which comprises: a nanoparticle containing with a first element, which is iron, copper, or the combination thereof; and a pharmaceutically acceptable carrier, wherein the nanoparticle is a metal nanoparticle, an alloy nanoparticle, or a metal nanoparticle with core-shell structure, and the size of the nanoparticle is under a controllable range of 3 nm to 150 nm. In addition, the present invention provides a detection method to detect radiation-sensitivity of the cancer cells through different modalities such as CT or MRI due to its native high CT number and magnetic property. Furthermore, the present invention provides a pharmaceutical composition for elevating radiation-sensitivity of the cancer cells through preferential uptake of the nanoparticle, in order to enhance the radiation-sensitivity of the cancer cells and improve the efficiency of radiation therapy to the cancer cells.Type: ApplicationFiled: September 27, 2012Publication date: July 4, 2013Inventors: Dar-Bin SHIEH, Hai-Wen CHEN, Chia-Chun CHEN, Ping-Ching WU
-
Publication number: 20130149539Abstract: Magnetic nanoparticles and related devices and methods are described. Compositions and methods can include magnetic nanoparticles having a narrow size distribution for use in diagnostics and therapeutics.Type: ApplicationFiled: June 20, 2011Publication date: June 13, 2013Applicant: University of Washington through Its Center for CommercializationInventors: Kannan M. Krishnan, R. Matthew Ferguson, Amit Praful Khandhar
-
Publication number: 20130129810Abstract: In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders.Type: ApplicationFiled: April 12, 2011Publication date: May 23, 2013Applicants: Tel Hashomer Medical Research Infrastructure and Services Ltd., RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: Jonathan Leor, Tamar Ben-Mordechai, Shimrit Adutler-Lieber, Rimona Margalit, Inbar Elron-Gross, Yifat Glucksam-Galnoy
-
Publication number: 20130125910Abstract: Provided are cosmetic compositions incorporating electrophoretic colorants than can effect stable and reversible changes in the color of the cosmetic in response to an electric field. The compositions provide for stable and reversible wearer determined changes in cosmetic color for lips, skin, hair and nails.Type: ApplicationFiled: November 18, 2011Publication date: May 23, 2013Applicant: AVON PRODUCTS, INC.Inventor: Amitabh Bansal
-
Patent number: 8445025Abstract: Disclosed are the nanoparticle and the method for the same, and the preparing method includes steps of mixing polyethylenimine (PEI) with the poly(acrylic acid)-bound iron oxide (PAAIO) to form a PEI-PAAIO polyelectrolyte complex (PEC) and mixing the PEI-PAAIO PEC with genetic material such as plasmid DNA to form the PEI-PAAIO/pDNA magnetic nanoparticle. The PEI-PAAIO/pDNA magnetoplex is highly water dispersible and suitable for long term storage, shows superparamagnetism, low cytotoxicity, high stability and nice transfection efficiency, and thus the PEI-PAAIO PEC can replace PEI as a non-viral gene vector.Type: GrantFiled: March 29, 2011Date of Patent: May 21, 2013Assignee: Kaohsiung Medical UniversityInventors: Li-Fang Wang, Shuo-Li Sun, Yu-Lun Lo
-
Patent number: 8440230Abstract: The present invention is related to a formulation based on micronized natural calcite mineral consisting of: A. mineral part which is characterized: (i) by the particle size with diameter smaller than 5 ?m, where the distribution of particle size is such that minimum of 10% of particles are with diameter under 900 nm, with total surface of particles greater than 3.2 m2/g, and with total porous volume greater than 0.012 cm3/g, and by composition: (ii) CaCO3, MgCO3, FeCO3, MnCO3, ZnCO3 and SiO2 in mixtures where CaCO3 is presented in amount from 10% to 99% of mineral part; and B. adjuvant selected from the group consisting of: wetting agent, drift-control agent at application by spraying, humic acid salt, amino-acids salts, complex of plant micro-nutrients, vitamin, plant hormone, nitrogen fertilizer, potassium salt, borate salt, molybdate salt, plant extract, chlorophyll, yeast extract, or mixture of these substances; where A. and B. form an aqueous suspension wherein percentage of A. and B.Type: GrantFiled: January 29, 2008Date of Patent: May 14, 2013Assignee: Mikro Mineral USA, Inc.Inventors: Antonio Lelas, Ivica Cepanec